Acute bilateral blindness in a young Covid-19 patient with rhino-orbito-cerebral mucormycosis

Malek, Ines; Sayadi, Jihene; Lahiani, Rim; Boumediene, Miriam; Salah, Memia Ben; Jrad, M.; Khairallah, Moncef; Nacef, L.

doi:10.1186/s12348-021-00272-0

Cited by 5 publications

(16 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Finally, 29 studies were included in the systematic review [ 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 ] and two in the meta-analysis [ 9 , 23 ]. The included studies provided data on the number of participants with “visual loss” developed during COVID-19, and the meta-analysis included two studies [ 9 , 23 ] with 288 COVID-19 patients.…”

Section: Resultsmentioning

confidence: 99%

“…The articles included in this systematic review were published between 28 April 2020 and 22 February 2022. We assessed two cross-sectional studies [ 9 , 23 ], twenty-four case reports [ 8 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 24 , 25 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 36 ], and three case series [ 14 , 26 , 35 ]. The number of participants ranged from one (case reports) to 199 (cross-sectional studies), with 84 out 318 COVID-19 patients experiencing “visual loss”.…”

Section: Resultsmentioning

confidence: 99%

“…Twenty-seven articles reported the age ((median ± standard deviation), (margin of error)): 46.28 ±3.03 (± 6.55%), n = 31) at the onset of COVID-19 [ 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 35 ], and twenty-nine articles [ 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 ,…”

Section: Resultsmentioning

confidence: 99%

“…”Visual loss” in COVID-19 patients was reported in a few articles. Nonetheless, it has been observed that its onset may be due to viral neurotropism and indirect immunologic and neurovascular effects [ 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 ].…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

“Vision Loss” and COVID-19 Infection: A Systematic Review and Meta-Analysis

Ripa

Motta

Schipa

et al. 2022

Vision

View full text Add to dashboard Cite

Background: Visual impairment in terms of reduced visual acuity and “visual loss” has been reported as an atypical symptom in patients with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection. This systematic review and meta-analysis aims to assess the cumulative incidence of “visual loss” during coronavirus disease 2019 (COVID-19) and review the current evidence regarding “visual loss” caused by SARS-CoV-2 infection. Methods: We performed a systematic review and meta-analysis of studies following Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. We systematically searched the PubMed, Embase, and Scopus databases for relevant studies published that clearly described “vision loss” and SARS-CoV-2 infection. All studies reporting concomitant “vision loss” and laboratory-confirmed SARS-CoV-2 infection were included. Meta-analyses were conducted using the measurement of risk and a 95% confidence interval for each study. Results: Our search identified 1143 manuscripts published in the English language. After study screening, twenty-nine articles were selected: two cross-sectional studies, twenty-four case reports, and three case series. A random-effect meta-analysis demonstrated that the pooled “visual loss” cumulative incidence in COVID-19 patients was 0.16 (95% CI 0.12–0.21). The quality rating of the cross-sectional studies averaged four out of the maximum score on the Newcastle–Ottawa scale. Conclusions: COVID-19 infection might cause “visual loss”. Even if the current evidence is limited, ophthalmological assessment should be promptly provided to all patients experiencing visual impairment symptoms during SARS-CoV-2 infection.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

“Vision Loss” and COVID-19 Infection: A Systematic Review and Meta-Analysis

Ripa

Motta

Schipa

et al. 2022

Vision

View full text Add to dashboard Cite

show abstract

“…Malek et al . [ 3 ] reported acute bilateral blindness in a young COVID-19 patient associated with ROCM. They noticed left cavernous sinus and internal carotid thrombosis along with CRAO in right eye.…”

Section: Discussionmentioning

confidence: 99%

Bilateral blindness in a young male of rhino-orbital-cerebral mucormycosis: A case report

Kaur

Sehgal²,

Khan³

et al. 2022

Indian J Ophthalmol

View full text Add to dashboard Cite

The storm of COVID-19-associated mucormycosis (CAM) has not yet settled, and it has proven itself a disfiguring and potentially life-threatening disease, complicating the course of COVID-19 infection. Mucormycosis is a rare but devastating fungal infection caused by filamentous fungi of the family Mucoraceae. We report a rare case of a 37-year-old diabetic male with bilateral rhino-orbital-cerebral mucormycosis (ROCM) where it leads to bilateral central retinal artery occlusion (CRAO) as manifestation of the disease. Bilateral CRAO secondary to ROCM is extremely rare. A strong suspicion of CAM in uncontrolled diabetics can result in early diagnosis and management.

show abstract

Rhino-orbital mucormycosis

Ryu

Laylani

Davila-Siliezar

et al. 2022

Current Opinion in Ophthalmology

View full text Add to dashboard Cite

Purpose of reviewThe current article will update and review the clinical and radiological manifestations and management of rhino-orbital mucormycosis (ROM).Recent findingsThere has been an increase in cases of ROM worldwide, especially in India. Immunosuppression (especially diabetes mellitus) is a known predisposing risk factor for ROM. Delayed diagnosis and treatment of ROM can be vision or life-threatening. This article reviews the clinical and radiologic features, treatment, and prognosis of ROM with special emphasis on new and emerging therapies.SummaryROM is an angioinvasive fungal infection that affects the sinuses and orbits and may present to ophthalmologists. Clinicians should have a high index of suspicion for ROM, especially in patients with poorly controlled diabetes mellitus or other immunosuppression. Corticosteroid treatment (including the recent COVID-19 pandemic) may be a predisposing risk factor for ROM.

show abstract

Acute bilateral blindness in a young Covid-19 patient with rhino-orbito-cerebral mucormycosis

Cited by 5 publications

References 5 publications

“Vision Loss” and COVID-19 Infection: A Systematic Review and Meta-Analysis

“Vision Loss” and COVID-19 Infection: A Systematic Review and Meta-Analysis

Bilateral blindness in a young male of rhino-orbital-cerebral mucormycosis: A case report

Rhino-orbital mucormycosis

Contact Info

Product

Resources

About